Browsing by Author "Vinh, Donald C"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • Thumbnail Image
    ItemOpen Access
    Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.
    (The Lancet. Infectious diseases, 2021-06) Koehler, Philipp; Bassetti, Matteo; Chakrabarti, Arunaloke; Chen, Sharon CA; Colombo, Arnaldo Lopes; Hoenigl, Martin; Klimko, Nikolay; Lass-Flörl, Cornelia; Oladele, Rita O; Vinh, Donald C; Zhu, Li-Ping; Böll, Boris; Brüggemann, Roger; Gangneux, Jean-Pierre; Perfect, John R; Patterson, Thomas F; Persigehl, Thorsten; Meis, Jacques F; Ostrosky-Zeichner, Luis; White, P Lewis; Verweij, Paul E; Cornely, Oliver A; European Confederation of Medical Mycology; International Society for Human Animal Mycology; Asia Fungal Working Group; INFOCUS LATAM/ISHAM Working Group; ISHAM Pan Africa Mycology Working Group; European Society for Clinical Microbiology; Infectious Diseases Fungal Infection Study Group; ESCMID Study Group for Infections in Critically Ill Patients; Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy; Medical Mycology Society of Nigeria; Medical Mycology Society of China Medicine Education Association; Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology; Association of Medical Microbiology; Infectious Disease Canada
    Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either voriconazole or isavuconazole. If azole resistance is a concern, then liposomal amphotericin B is the drug of choice. Our aim is to provide definitions for clinical research and up-to-date recommendations for clinical management of the diagnosis and treatment of COVID-19-associated pulmonary aspergillosis.
  • Thumbnail Image
    ItemOpen Access
    Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM
    (The Lancet Infectious Diseases, 2025-02) Cornely, Oliver A; Sprute, Rosanne; Bassetti, Matteo; Chen, Sharon C-A; Groll, Andreas H; Kurzai, Oliver; Lass-Flörl, Cornelia; Ostrosky-Zeichner, Luis; Rautemaa-Richardson, Riina; Revathi, Gunturu; Santolaya, Maria E; White, P Lewis; Alastruey-Izquierdo, Ana; Arendrup, Maiken C; Baddley, John; Barac, Aleksandra; Ben-Ami, Ronen; Brink, Adrian J; Grothe, Jan H; Guinea, Jesus; Hagen, Ferry; Hochhegger, Bruno; Hoenigl, Martin; Husain, Shahid; Jabeen, Kauser; Jensen, Henrik E; Kanj, Souha S; Koehler, Philipp; Lehrnbecher, Thomas; Lewis, Russell E; Meis, Jacques F; Nguyen, M Hong; Pana, Zoi D; Rath, Peter-Michael; Reinhold, Ilana; Seidel, Danila; Takazono, Takahiro; Vinh, Donald C; Zhang, Sean X; Afeltra, Javier; Al-Hatmi, Abdullah MS; Arastehfar, Amir; Arikan-Akdagli, Sevtap; Bongomin, Felix; Carlesse, Fabianne; Chayakulkeeree, Methee; Chai, Louis YA; Chamani-Tabriz, Leili; Chiller, Tom; Chowdhary, Anuradha; Clancy, Cornelius J; Colombo, Arnaldo L; Cortegiani, Andrea; Corzo Leon, Dora E; Drgona, Lubos; Dudakova, Anna; Farooqi, Joveria; Gago, Sara; Ilkit, Macit; Jenks, Jeffrey D; Klimko, Nikolai; Krause, Robert; Kumar, Anil; Lagrou, Katrien; Lionakis, Michail S; Lmimouni, Badre E; Mansour, Michael K; Meletiadis, Joseph; Mellinghoff, Sibylle C; Mer, Mervyn; Mikulska, Malgorzata; Montravers, Philippe; Neoh, Chin Fen; Ozenci, Volkan; Pagano, Livio; Pappas, Peter; Patterson, Thomas F; Puerta-Alcalde, Pedro; Rahimli, Laman; Rahn, Sebastian; Roilides, Emmanuel; Rotstein, Coleman; Ruegamer, Tamara; Sabino, Raquel; Salmanton-García, Jon; Schwartz, Ilan S; Segal, Esther; Sidharthan, Neeraj; Singhal, Tanu; Sinko, Janos; Soman, Rajeev; Spec, Andrej; Steinmann, Joerg; Stemler, Jannik; Taj-Aldeen, Saad J; Talento, Alida Fe; Thompson, George R; Toebben, Christina; Villanueva-Lozano, Hiram; Wahyuningsih, Retno; Weinbergerová, Barbora; Wiederhold, Nathan; Willinger, Birgit; Woo, Patrick CY; Zhu, Li-Ping
  • Thumbnail Image
    ItemOpen Access
    Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScopeⓇ-Global Registry for Emerging Fungal Infections.
    (The Journal of infection, 2020-11) Salmanton-García, Jon; Koehler, Philipp; Kindo, Anupma; Falces-Romero, Iker; García-Rodríguez, Julio; Ráčil, Zdeněk; Chen, Sharon C-A; Klimko, Nikolai; Desoubeaux, Guillaume; Thompson, George R; Benítez-Peñuela, Miguel-Ángel; Rodríguez, José-Yesid; Sheppard, Donald C; Hoenigl, Martin; Le Govic, Yohann; Badali, Hamid; Baddley, John W; Chander, Jagdish; Ingram, Paul R; Pakstis, Diana L; Mellinghoff, Sibylle C; Atıcı, Serkan; Cesaro, Simone; Chakrabarti, Arunaloke; Dupont, Damien; González, Gloria M; Hatvani, Lóránt; Herbrecht, Raoul; Klyasova, Galina; Lass-Flörl, Cornelia; Mareș, Mihai; Mullane, Kathleen; Vinh, Donald C; Wisplinghoff, Hilmar; Lackner, Michaela; Cornely, Oliver A; Seidel, Danila; ECMM/ISHAM working group

    Objectives

    Emerging invasive fungal infections (IFI) have become a notable challenge. Apart from the more frequently described fusariosis, lomentosporiosis, mucormycosis, scedosporiosis, and certain dematiaceae or yeasts, little is known about extremely rare IFI.

    Methods

    Extremely rare IFI collected in the FungiScopeⓇ registry were grouped as Dematiaceae, Hypocreales, Saccharomycetales, Eurotiales, Dermatomycetes, Agaricales, and Mucorales.

    Results

    Between 2003 and June 2019, 186 extremely rare IFI were documented in FungiScopeⓇ. Dematiaceae (35.5%), Hypocreales (23.1%), Mucorales (11.8%), and Saccharomycetales (11.3%) caused most IFI. Most patients had an underlying malignancy (38.7%) with acute leukemia accounting for 50% of cancers. Dissemination was observed in 26.9% of the patients. Complete or partial clinical response rate was 68.3%, being highest in Eurotiales (82.4%) and in Agaricales (80.0%). Overall mortality rate was 29.3%, ranging from 11.8% in Eurotiales to 50.0% in Mucorales.

    Conclusions

    Physicians are confronted with a complex variety of fungal pathogens, for which treatment recommendations are lacking and successful outcome might be incidental. Through an international consortium of physicians and scientists, these cases of extremely rare IFI can be collected to further investigate their epidemiology and eventually identify effective treatment regimens.